8-K: Orchestra BioMed Secures $70 Million in Strategic Capital from Ligand and Medtronic, Expands Leadless Pacemaker Collaboration

Orchestra BioMed Holdings, Inc. announced a significant $70 million capital infusion from Ligand Pharmaceuticals and Medtronic, alongside an expanded strategic collaboration with Medtronic to integrate AVIM therapy into future leadless pacemakers.

Summary

• Orchestra BioMed secured $70.0 million in new capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage partnered cardiology programs.
• Ligand Pharmaceuticals invested $35.0 million for a tiered revenue participation right on future sales of the company's BACKBEAT Cardiac Neuromodulation Therapy (AVIM therapy) and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), with an additional $5.0 million equity private placement.
• Medtronic provided a $20.0 million secured subordinated convertible promissory note, funding on April 27, 2026, and committed to purchase up to $12.0 million in common stock through a private placement.
• The Medtronic convertible note accrues simple interest at 11% per annum and automatically converts into a 15% revenue share credit (up to $40.0 million) upon FDA approval of a Medtronic device incorporating AVIM therapy.
• The existing Exclusive License and Collaboration Agreement with Medtronic was amended to establish a development and commercialization framework for future AVIM-therapy integration into dual-chamber leadless pacemakers.
• The company amended its Loan and Security Agreement with Hercules Capital, Inc., delaying the initial term loan amortization date from December 1, 2026 (or December 1, 2027) to July 1, 2027 (or January 1, 2028) and increasing borrowing capacity by $15.0 million to $35.0 million.
• The company will issue warrants to Ligand for up to 2,000,000 shares, vesting in two tranches (1,142,857 shares on issue date, 857,143 shares on second installment payment) and exercisable for ten years.
• Hercules warrants were amended, adjusting the exercise price to the lower of $5.74 or 130% of the next equity financing price, and increasing the number of issuable shares from 2% to 4% of the aggregate principal amount of Term Loan Advances.
• The company expects its cash, cash equivalents, and short-term investments to be approximately $33.9 million as of June 30, 2025 (unaudited preliminary results).
• A shelf registration statement on Form S-3 will be filed within 90 calendar days of the Stock Purchase Agreements closing to register the resale of private placement shares and warrant shares.

Sentiment

Score: 7

Explanation: The filing indicates a strong positive development with a significant capital infusion and expanded strategic partnerships, validating the company's product pipeline. However, minor delays in clinical trials and potential increases in royalty rates based on performance introduce some cautionary elements, preventing a 'strong buy' sentiment.

Positives

• Secured a substantial $70.0 million in new capital, significantly strengthening the financial position and providing foundational support for clinical programs.
• Attracted strategic investments from Ligand Pharmaceuticals and Medtronic, indicating strong confidence in the company's scientific advancements and product pipeline.
• Expanded collaboration with Medtronic to include the potential integration of AVIM therapy into future leadless pacemakers, opening new market opportunities and deepening strategic alignment.
• Delayed the initial amortization date for Hercules term loans from December 1, 2026 (or December 1, 2027) to July 1, 2027 (or January 1, 2028), providing increased financial flexibility.
• Increased the discretionary borrowing capacity under the Hercules loan by $15.0 million, from $20.0 million to $35.0 million.
• The exercise price for Hercules warrants was adjusted to be the lower of $5.74 or 130% of the next equity financing price, potentially favorable for the company depending on future equity pricing.
• The company committed to filing a shelf registration statement for the resale of private placement shares and warrant shares, which will provide liquidity for investors.
• FDA-approved amendments to the BACKBEAT study protocol are expected to significantly expand patient eligibility and streamline study workflow.
• The company intends to initiate enrollment of the Virtue SAB trial in the U.S. during the second half of 2025, regardless of the ongoing Terumo mediation.

Negatives

• Ligand's revenue interest rates will incrementally increase from 17.0% to 20.0% and 4.0% to 7.0% if certain BACKBEAT clinical study enrollment milestones are not achieved by specified dates (October 1, 2026, November 16, 2026, and January 1, 2027).
• The $20.0 million Medtronic loan is subordinated to senior obligations and cannot be prepaid without Medtronic's prior written consent, limiting financial flexibility.
• The company eliminated its ability to draw up to an additional $15.0 million under the Hercules loan if certain milestones were achieved.
• The ongoing mediation procedure with Terumo Corporation regarding the distribution agreement could adversely impact commercialization plans for Virtue SAB if not resolved favorably.
• The expected completion of enrollment for the BACKBEAT study has been pushed back from the 'first half of 2026' to 'mid-2026'.

Risks

• If the formal mediation with Terumo does not lead to a timely agreement or resolution, or if the company does not prevail in arbitration, or if the Terumo Agreement is terminated, commercialization plans for Virtue SAB may be adversely impacted.
• Forward-looking statements are subject to risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions.
• Risks related to regulatory approval of the company's product candidates.
• The timing of, and the company's ability to achieve, expected regulatory and business milestones.
• The impact of competitive products and product candidates.
• Preliminary financial results are based on management's initial review and are subject to completion of financial closing procedures, potentially differing materially from actual results.
• If the Second Installment of $15.0 million from Ligand is not paid due to unmet conditions, the Ligand warrant will only be exercisable with respect to the First Tranche of 1,142,857 shares.
• The effectiveness of the Medtronic Collaboration Agreement Amendment is contingent on the Medtronic Loan proceeds being used solely for the continued funding and support of the BACKBEAT clinical study and directly associated activities.
• The effectiveness of the Hercules Loan and Security Agreement Amendment is contingent on the company receiving $70.0 million in aggregate gross proceeds from various financing activities.

Future Outlook

The company expects to file a registration statement on Form S-3 to register the resale of warrant shares and private placement shares within 90 calendar days of the Stock Purchase Agreements closing. It aims to achieve effectiveness of this registration statement as early as possible, but no later than 180 days if reviewed by the SEC, or 5 business days if not reviewed. The company intends to initiate enrollment of the Virtue SAB trial in the U.S. during the second half of 2025 and expects enrollment for the BACKBEAT study to be completed in mid-2026. The expanded collaboration with Medtronic provides a framework for future AVIM-therapy integration into leadless pacemakers.

Management Comments

• Todd Davis, CEO of Ligand, stated, "We are pleased to partner with Medtronic and Orchestra BioMed in this important endeavor. This investment expands our pipeline of development-stage products and demonstrates our confidence in Orchestra BioMeds scientific advancements, as well as the strong capabilities of its partner, Medtronic. We are proud to support Orchestra BioMed as they develop novel high-impact, device-based therapies such as AVIM therapy and Virtue SAB targeting high-risk patient populations with hypertension and arterial disease, two of the most significant global health challenges."
• David Hochman, Chairman and CEO of Orchestra BioMed, commented, "Ligand has been one of the inspirations for our partnership-driven approach to creating long-term, capital-efficient value through royalty-based collaborations. We are thrilled to welcome them as a strategic capital partner. Ligands decision to invest in our partnered programs and our team reflects our shared conviction in the transformative potential of both AVIM therapy and Virtue SAB – our late-stage flagship technologies aimed to address important unmet medical needs in large, established global markets. This transaction provides foundational financial support to enable our potential achievement of key value creating milestones for both of our high-impact clinical programs."
• Robert C. Kowal, M.D., Ph.D., VP and General Manager of Cardiac Pacing Therapies within Medtronic, stated, "Our expanded investment in Orchestra BioMed reflects confidence in their clinical progress. Broadening our collaboration to include integrating AVIM therapy into future leadless pacing technology reaffirms our commitment to transform care for patients who need pacing therapy and have uncontrolled hypertension."
• Mr. Hochman added, "Medtronic continues to be an outstanding partner for the AVIM therapy program. We believe their $30 million additional commitment to Orchestra BioMed reflects their belief in the clinical and commercial potential for this therapy to benefit patients with uncontrolled hypertension and increased cardiovascular risk in the pacemaker population. Expanding our existing collaboration to provide for potential future integration of AVIM therapy into a leadless pacemaker system deepens our strategic alignment and creates a potential pathway for patients to benefit from both AVIM therapy and cutting-edge leadless pacing technology, simultaneously."

Industry Context

The announcement reflects a growing trend in the biomedical device industry towards strategic partnerships and diversified financing models, particularly for companies with promising late-stage clinical assets. By securing significant capital from established players like Ligand and Medtronic, Orchestra BioMed is leveraging a capital-efficient, royalty-based collaboration model, similar to those seen in the biopharmaceutical sector. The focus on hypertension and arterial disease aligns with major global health priorities, and the expansion into leadless pacemaker technology with Medtronic indicates a move towards less invasive and more integrated therapeutic solutions in cardiovascular care.

Comparison to Industry Standards

• The company's 'risk-reward sharing partnerships' with leading medical device companies like Medtronic and Terumo are a recognized strategy for capital-efficient development in the medical device industry, mirroring successful royalty financing models in the broader life sciences sector.
• The receipt of four FDA Breakthrough Device Designations for AVIM therapy and Virtue SAB highlights the potential of these technologies to address significant unmet medical needs, positioning them favorably against existing or developing standard therapies in their respective fields.
• The ability to secure $70.0 million in strategic capital from industry leaders like Ligand and Medtronic, including a convertible loan and revenue participation rights, demonstrates strong market validation and confidence in the company's pipeline, which is a positive indicator compared to smaller companies struggling to attract such substantial investments.

Corporate Governance

Legal Proceedings

• The company is in a mediation procedure with Terumo Corporation and Terumo Medical Corporation (collectively, Terumo) pursuant to a distribution agreement, intended to assist in potentially resolving disagreements and facilitating the completion of negotiations related to restructuring, replacing, or terminating the Terumo Agreement.
• Matters not resolved through mediation are to be resolved by binding arbitration conducted under the auspices of the International Centre for Dispute Resolution (ICDR) in accordance with its International Arbitration Rules.

Related Party Transactions

• Orchestra BioMed Holdings, Inc. entered into a Revenue Participation Right Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated.
• Orchestra BioMed Holdings, Inc. entered into a Stock Purchase Agreement with Ligand Pharmaceuticals Incorporated.
• Orchestra BioMed Holdings, Inc. and its wholly-owned subsidiaries (Orchestra BioMed, Inc. and BackBeat Medical, LLC) entered into a Loan Agreement with Medtronic Inc.
• Orchestra BioMed Holdings, Inc. entered into a Stock Purchase Agreement with Covidien Group S.a.r.l., an affiliate of Medtronic Inc.
• Orchestra BioMed Holdings, Inc., BackBeat Medical, LLC, and Medtronic entered into an amendment to their Exclusive License and Collaboration Agreement.
• Orchestra BioMed Holdings, Inc. and certain of its subsidiaries entered into a second amendment to the Loan and Security Agreement with Hercules Capital, Inc. and other lenders.
• Orchestra BioMed Holdings, Inc. entered into amendments to warrant agreements with the lenders under the Loan and Security Agreement (Hercules Warrant Agreements).

Stakeholder Impact

• **Shareholders**: Potential dilution from new equity issuances and warrants, but also significant capital infusion and strategic partnerships that could drive long-term value. Increased liquidity through planned registration statement.
• **Employees**: Continued funding for clinical programs supports ongoing research and development efforts, potentially ensuring job stability and future growth opportunities.
• **Customers/Patients**: Expanded collaboration with Medtronic for leadless pacemakers and continued development of AVIM therapy and Virtue SAB aim to bring innovative treatments to patients with hypertension and arterial disease.
• **Creditors (Hercules Capital, Inc.)**: Loan amortization payments are delayed, providing the company with more time to generate revenue before significant repayments are due. Increased borrowing capacity also indicates continued support.
• **Partners (Ligand, Medtronic, Terumo)**: Deepened strategic alignment with Ligand and Medtronic through new investments and expanded collaborations. The ongoing mediation with Terumo could impact that partnership.

Next Steps

• The company expects to file a registration statement on Form S-3 to register the resale of private placement shares and warrant shares within 90 calendar days of the Stock Purchase Agreements closing.
• The company will use commercially reasonable efforts to cause the registration statement to be declared effective at the earliest possible date, but no later than 180 days (if SEC review) or 5 business days (if no SEC review) following the issuance of the Private Placement Shares.
• The company intends to initiate enrollment of the Virtue SAB trial, its pivotal study for coronary in-stent restenosis in the U.S., during the second half of 2025.
• The company will continue other product development efforts related to Virtue SAB.
• The company expects enrollment of the BACKBEAT study to be completed in mid-2026.
• The company is in the process of implementing additional FDA-approved amendments to the BACKBEAT global pivotal study to expand patient eligibility and streamline workflow.
• The Medtronic convertible loan of $20.0 million is scheduled to be funded on April 27, 2026.
• The second installment of $15.0 million from Ligand is payable 270 days following the closing of the transaction, subject to certain conditions.

Key Dates

Recommendation

The company has secured a substantial $70 million in new capital from key strategic partners, Ligand and Medtronic, which significantly de-risks its financial position and validates its late-stage product pipeline. The expanded collaboration with Medtronic for leadless pacemakers opens a promising new avenue for AVIM therapy. However, the potential for increased royalty rates to Ligand if clinical milestones are missed, the ongoing legal mediation with Terumo, and the slight delay in the BACKBEAT study's enrollment completion introduce elements of uncertainty. While the overall outlook is positive due to the funding and partnerships, these factors suggest a 'hold' recommendation until further clarity on clinical progress and dispute resolution is achieved, allowing investors to monitor execution and milestone achievement.

Keywords

Biomedical, Medical Device, Cardiology, Hypertension, Arterial Disease, AVIM Therapy, Virtue SAB, Pacemaker, Leadless Pacemaker, Clinical Trials, BACKBEAT Study, SEC Filings, Capital Raise, Strategic Partnership, Royalty Financing, Convertible Note, Debt Financing, Equity Private Placement, Corporate Governance, Risk Management, Regulatory Approval, FDA Breakthrough Device Designation